Sapient Capital’s DexCom DXCM Stock Holding History

Sapient Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,917	Closed	-$309K	–	428
2026 Q1	$309K	Buy	+4,917	New	+$342K	﹤0.01%	352
2024 Q4	–	Sell	-5,464	Closed	-$366K	–	381
2024 Q3	$366K	Buy	+5,464	New	+$449K	0.01%	289

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sapient Capital's DXCM Position: Q2 2026 in Review

Sapient Capital sold out of DexCom (DXCM) in Q2 2026, closing a stake of 4,917 shares — an estimated $309K sold.

Sapient Capital first reported a position in DXCM in Q3 2024 and held it in 2 quarters. The position peaked at $366K in Q3 2024. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

Sapient Capital reported no remaining DexCom position as of Q2 2026 after selling out during the quarter.
Sapient Capital sold 4,917 DexCom shares in Q2 2026, an estimated $309K.
Sapient Capital first reported a position in DexCom in Q3 2024 and held it in 2 quarters.
Sapient Capital's DexCom position peaked at $366K in Q3 2024.
968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Sapient Capital's 13F filing for Q2 2026, filed 9 Jul 2026.